Benzinga · Oct 30, 2026
TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100
TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $110 to $100.
NASDAQ · BBIO
BridgeBio Pharma, Inc.
Healthcare · Biotechnology
$75.00
Up+$0.05 (+0.06%)
Updated Nov 3, 2026, 7:33 AM
SID Score
5.9/10
Composite research score
Smart Money
47/100
Neutral
- Market cap
- 14.11B
- P/E ratio
- -17.71
- Dividend yield
- 0.00%
- 52-week range
- $60.22 – $93.42
- Volume
- 3.1M
- Avg. volume
- 2.32M
Price performance · BBIO
BBIO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
BBIO closed at $75.00 after 21 trading sessions, up 13.39% for the selected period.
- Last close
- $75.00
- Period change
- +13.39%
- Period low
- $63.30
- Period high
- $75.00
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $74.96 | $76.70 | $74.20 | $74.995 | 3.1M |
| Oct 30, 2026 | $72.85 | $75.85 | $71.90 | $74.95 | 5.77M |
| Oct 29, 2026 | $71.37 | $73.05 | $70.21 | $70.73 | 4.93M |
| Oct 28, 2026 | $69.10 | $71.18 | $68.65 | $70.82 | 3.11M |
| Oct 27, 2026 | $68.135 | $69.64 | $67.99 | $69.37 | 2.04M |
| Oct 26, 2026 | $68.56 | $68.83 | $67.865 | $68.15 | 2.06M |
| Oct 23, 2026 | $67.69 | $68.86 | $67.02 | $68.56 | 2.4M |
| Oct 22, 2026 | $67.48 | $69.32 | $67.0744 | $68.12 | 2.78M |
| Oct 21, 2026 | $68.04 | $68.79 | $67.545 | $67.74 | 3.01M |
| Oct 20, 2026 | $68.28 | $69.00 | $67.25 | $67.55 | 2.73M |
| Oct 19, 2026 | $67.35 | $68.52 | $66.725 | $67.94 | 2.29M |
| Oct 16, 2026 | $67.03 | $67.04 | $65.26 | $66.39 | 2.06M |
| Oct 15, 2026 | $65.67 | $67.7625 | $65.435 | $67.13 | 2.64M |
| Oct 14, 2026 | $63.34 | $65.36 | $62.86 | $64.94 | 2.7M |
| Oct 13, 2026 | $66.05 | $66.05 | $62.94 | $63.30 | 2.71M |
| Oct 12, 2026 | $65.35 | $66.415 | $65.20 | $65.75 | 1.78M |
| Oct 9, 2026 | $65.04 | $65.94 | $64.34 | $65.35 | 1.85M |
| Oct 8, 2026 | $66.39 | $66.405 | $63.70 | $65.04 | 3.36M |
| Oct 7, 2026 | $66.78 | $67.585 | $66.15 | $66.50 | 2.06M |
| Oct 6, 2026 | $67.75 | $68.12 | $65.705 | $66.96 | 3.71M |
| Oct 5, 2026 | $67.40 | $68.08 | $65.46 | $66.14 | 2.17M |
Latest BBIO news
The latest Smart Investors Daily articles mentioning BBIO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BBIO research
Overview
Company profile and research snapshot.
Company profile
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $85.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 2, 2026 | Canaccord Genuity | Buy | — |
| Oct 30, 2026 | TD Cowen | Buy | — |
| Oct 30, 2026 | Morgan Stanley | Overweight | — |
| Oct 21, 2026 | Morgan Stanley | Overweight | — |
| Oct 19, 2026 | Piper Sandler | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 30, 2026
BridgeBio (BBIO) Q3 2026 Earnings Call Transcript
Revenue surged to $353.2 million as Attruby gains traction in rare disease markets.
Benzinga · Oct 30, 2026
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $87 to $88.
Yahoo · Oct 30, 2026
BridgeBio Pharma, Inc. Q3 2026 Earnings Call Summary
Moby summary of BridgeBio Pharma, Inc.'s Q3 2026 earnings call
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
